Jeanne M. Schilder | Academic Influence

Jeanne M. Schilder's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

Identification and characterization of ovarian cancer-initiating cells from primary human tumors. (1174)
Epigenetic resensitization to platinum in ovarian cancer. (294)
Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. (180)
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer (141)
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. (128)
A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgery. (116)
Cell Origins of High-Grade Serous Ovarian Cancer (101)
Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. (94)
Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. (80)
A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. (66)
Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum‐resistant ovarian cancer and primary peritoneal carcinomatosis (66)
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. (54)
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. (52)
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. (46)
The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer (44)
Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer (43)
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. (40)
Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. (38)
Work teams boost productivity (30)
Hormonal treatment of an endometrial stromal nodule followed by local excision. (29)
Is a third-trimester antibody screen in Rh+ women necessary? (28)
Prognosis of Patients Who Relapse after Fertility-Sparing Surgery in Epithelial Ovarian Cancer (28)
Primary appendiceal cancer: gynecologic manifestations and treatment options. (26)
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. (21)
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. (20)
Indiana University Experience in the Management of Vaginal Cancer (20)
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. (15)
breast cancer, early stageInterim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR + /HER2- breast cancer (BC) (14)
A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. (13)
Symptoms of Pelvic Floor Disorders and Quality of Life Measures in Postoperative Patients With Endometrial Cancer (12)
Representations of Vaginal Symptoms in Cervical Cancer Survivors (11)
Complete hydatidiform mole coexisting with a twin live fetus: clinical course. (11)
Patient Recall of Health Care Events and Time to Diagnose a Suspected Ovarian Cancer (10)
A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC). (10)
Hematometra after thermal balloon endometrial ablation in a patient with cervical incompetence. (9)
Invasive Cancer of the Vulva (9)
Occult bladder injury during laparoscopy: report of two cases. (7)
Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH) (5)
Prolonged survival after episiotomy recurrence of cervical cancer complicating pregnancy. (5)
Concurrent chemotherapy and radiation therapy in primary cancer of the cervix (5)
Location of the transverse colon in relationship to the umbilicus: implications for laparoscopic techniques. (4)
A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: HOG GYN-111. (4)
A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). (4)
The Morphology Index: predictive value of malignancy among clinicians at various levels of training. (4)
Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer. (3)
Results of Gynecologic Oncology Group (GOG) 229 K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma (3)
Stage Ia-IIa cancer of the cervix. (3)
LAPAROSCOPIC SECONDARY PORT CONVERSION USING A REUSABLE BLUNT CONICAL TROCAR (3)
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group (GOG) study (3)
Germ Cell Tumors of the Ovary (1)
Phase II open-label, safety, pharmacokinetic and efficacy study of Panzem® NCD administered orally to patients with ovarian cancer (1)
Preoperative work up (1)
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer. (0)
“Whatʼs in a Name? That Which We Call a Rose, by Any Other Name …”* (0)
Abstract 14: Low molecular weight heparin: Is there a difference between preoperative administration versus postoperative administration? (0)
The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer (0)
Dentists add microprocessors to armamentarium. (0)
Wound morbidity of groin node dissection performed after radiation for vulvar cancer (0)
Abstract B273: A phase I trial of topotecan and sorafenib for patients with recurrent, platinum‐resistant epithelial ovarian cancer (0)
Chemotherapy in pregnancy (0)
"What's in a name? That which we call a rose, by any other name.". (0)
Abstract 4275: PLA2activities in human epithelial ovarian cancer ascites (0)
The Emerging Role of Molecular Testing in Ovarian Cancer (0)
Hemostatic efficacy of an advanced bipolar sealer in open gynecologic, thoracic, and colectomy procedures: A prospective cohort study (0)
Bowel Considerations in Gynecologic Surgery (0)
Tumor collection/processing under physioxia uncovers highly relevant signaling networks and drug sensitivity (0)
Chronic pelvic pain and endometriosis (0)
Treatment delays using an automated afterloading low-dose-rate brachytherapy system. (0)
A Novel Use of Laryngoscope for Difficult Papanicolaou Smear Collection (0)

This paper list is powered by the following services:

Other Resources About Jeanne M. Schilder

medicine.iu.edu

What Schools Are Affiliated With Jeanne M. Schilder?

Jeanne M. Schilder is affiliated with the following schools:

Marymount University
United States Coast Guard Academy
Indiana University–Purdue University Indianapolis
Indiana University